The developing landscape of drug therapy demands a re-evaluation of established approaches. Present research is shifting focus towards personalized treatment strategies, incorporating genomics, proteomics, and other cutting-edge biomarkers to foresee subject response and lessen adverse reactions. This emerging paradigm emphasizes targeted intervent